Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Edgewise Therapeutics Inc (EWTX)

Edgewise Therapeutics Inc (EWTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,984,280
  • Shares Outstanding, K 107,271
  • Annual Sales, $ 0 K
  • Annual Income, $ -167,800 K
  • EBIT $ -191 M
  • EBITDA $ -197 M
  • 60-Month Beta 0.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.76

Options Overview Details

View History
  • Implied Volatility 88.09% (+15.58%)
  • Historical Volatility 43.99%
  • IV Percentile 36%
  • IV Rank 19.20%
  • IV High 270.13% on 10/22/25
  • IV Low 44.82% on 06/26/25
  • Expected Move (DTE 13) 4.00 (14.36%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 8
  • Volume Avg (30-Day) 198
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 9,062
  • Open Int (30-Day) 10,084
  • Expected Range 23.83 to 31.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.49
  • Number of Estimates 7
  • High Estimate -0.39
  • Low Estimate -0.58
  • Prior Year -0.43
  • Growth Rate Est. (year over year) -13.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.82 +3.71%
on 03/06/26
31.82 -12.57%
on 02/25/26
-1.28 (-4.40%)
since 02/06/26
3-Month
19.76 +40.79%
on 12/22/25
31.82 -12.57%
on 02/25/26
+4.23 (+17.93%)
since 12/05/25
52-Week
10.60 +162.45%
on 04/07/25
31.82 -12.57%
on 02/25/26
-0.31 (-1.10%)
since 03/06/25

Most Recent Stories

More News
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026

BOULDER, Colo. , March 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present...

EWTX : 27.82 (-2.01%)
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference

BOULDER, Colo. , March 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 2026 Muscular...

EWTX : 27.82 (-2.01%)
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo. , March 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...

EWTX : 27.82 (-2.01%)
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs

–  CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026  –

EWTX : 27.82 (-2.01%)
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026

BOULDER, Colo. , Feb. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Behrad Derakhshan, Ph.D., Chief...

EWTX : 27.82 (-2.01%)
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo. , Feb. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...

EWTX : 27.82 (-2.01%)
Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026

- Advancing robust clinical pipeline of novel therapeutics for muscular dystrophies and serious cardiac conditions -

EWTX : 27.82 (-2.01%)
Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

BOULDER, Colo. , Jan. 6, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Kevin Koch, Ph.D., President and...

EWTX : 27.82 (-2.01%)
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo. , Jan. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...

EWTX : 27.82 (-2.01%)
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy

–  In the CIRRUS-HCM trial, including interim safety results from Part D, EDG-7500 was generally well tolerated; n o clinically meaningful reductions in LVEF or LVEF

EWTX : 27.82 (-2.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Edgewise Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing orally bioavailable, small molecule therapies for rare muscle disorders. Edgewise Therapeutics Inc. is based in Boulder, United States.

See More

Key Turning Points

3rd Resistance Point 29.58
2nd Resistance Point 28.83
1st Resistance Point 28.33
Last Price 27.82
1st Support Level 27.07
2nd Support Level 26.32
3rd Support Level 25.81

See More

52-Week High 31.82
Last Price 27.82
Fibonacci 61.8% 23.71
Fibonacci 50% 21.21
Fibonacci 38.2% 18.71
52-Week Low 10.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar